Journal of Peking University (Health Sciences) ›› 2021, Vol. 53 ›› Issue (3): 536-542. doi: 10.19723/j.issn.1671-167X.2021.03.016

Previous Articles     Next Articles

Analysis of the development trend and severity of the COVID-19 panidemic in the global world

HUANG Bing,WANG Hong-yuanΔ()   

  1. Department of Epidemiology and Health Statistics, Peking University School of Public Health, Beijing 100191, China
  • Received:2021-01-21 Online:2021-06-18 Published:2021-06-16
  • Contact: Hong-yuan WANG E-mail:why_w2003@163.com
  • Supported by:
    Anti-epidemic Project of Peking University(PKU2020PKYZX002)

Abstract:

Objective: To analyze the recent severity of COVID-19 in various countries. Methods: Data were ollected on the epidemic situation of COVID-19 in various countries as of January 16, 2021, and the scale and overall trend of the epidemic were retrospectively described; combined with the recent trend of newly confirmed cases, from January 10 to 16 (the 54th week) and the newly confirmed cases indexes, such as the number and incidence density the severity of the epidemic was classified. Feasible suggestions were put forward based on the variation of the virus,actual data of vaccine research and development and possible existence in many countries. Results: Up to January 16, 2021, there were 92 510 419 confirmed cases worldwide; 4 849 301 new confirmed cases were confirmed in the 54th week, and they were still growing. Among all the continents, the cumulative number of confirmed cases in Europe, North America, and Asia has exceeded 21 million, and the number of new confirmed cases in a single week in North America, South America and Asia were all increasing. Among the countries, the cumulative number of confirmed cases in 18 countries including the United States, India, and Brazil was more than 1 million, accounting for 77.04% of the total number of cumulative confirmed cases in the world. Eleven countries including the United States, Brazil, France, Spain, Colombia, The United Kingdom, Russia, Germany, South Africa, Italy, and India are at higher risk of the epidemic; The United States, Brazil, France, Spain, and Colombia were still experiencing new confirmed cases and increasing status, the risk of the epidemic was greater. Novel coronavirus mutates frequently, up to February 2021, there had been 3 931 mutant genotypes in the world. At the same time, a total of 11 vaccines were successfully launched, however we were still facing some troubles, such as the global shortage of vaccines, the public’s willingness to vaccinate needed to be improved, and equity in the distribution of vaccines. Conclusion: The global epidemic situation is still getting worse, with repeated epidemics in all the continents and countries, and has not been fundamentally controlled. At the continent level, North America, South America, and Europe have the most severe epidemics; at the national level, The United States, Brazil, France, Spain, Colombia and other countries have higher epidemic risks. Focusing on the severely affected countries will help bring the global epidemic under control as soon as possible. Under the premise of ensuring the safety and effectiveness of the vaccines, it is a key and feasible direction to improve the yield and vaccination rate of the vaccines, shorten the onset time of the vaccines and prolong the immune persistence.

Key words: COVID-19, Global, Development trend, Severity

CLC Number: 

  • R181.8

Table 1

Countries/region in a state of recent increase"

Country/region Newly diagnosed
in the 54th week
Incidence density
in the 54th week/%
Country/region Newly diagnosed
in the 54th week
Incidence density
in the 54th week/%
Brazil 1 362 621 1.71 French Polynesia 394 1.40
Colombia 111 754 2.20 Turks and Caicos Islands 106 2.74
Mexico 94 800 0.74 Philippines 4 12 794 0.12
Turkey 65 534 0.78 Ecuador 7 718 0.44
Canada 53 757 1.42 Guatemala 5 496 0.31
Lebanon 33 147 4.86 Libya 4 015 0.58
Bolivia 12 125 1.04 Venezuela 3 093 0.11
Dominican Republic 10 431 0.96 Ivory Coast 1 683 0.06
Paraguay 6 784 0.95 Ghana 1 520 0.05
Honduras 6 406 0.65 Haiti 394 0.03
Latvia 6 284 3.33 Guyana 276 0.35
Uruguay 6 182 1.78 Madagascar 234 0.01
Lesotho 3 794 1.77 Gabon 125 0.06
Mayotte 379 1.39 Martinique 110 0.29
Indonesia 2 74 078 0.27 Benin 109 0.01
Malaysia 19 958 0.62 Liberia 82 0.02
Zimbabwe 6 449 0.43 America 5 1 650 268 4.99
Mozambique 3 787 0.12 France 124 106 1.90
Cuba 3 273 0.29 Spain 122 348 2.62
Malawi 2 569 0.13 Portugal 61 760 6.06
Democratic Republic of Congo 1 889 0.02 Israel 48 617 5.62
Senegal 1 724 0.10 Peru 21 972 0.67
Rwanda 1 515 0.12 United Arab Emirates 21 672 2.19
Chad 388 0.02 Tunisia 20 162 1.71
Togo 375 0.05 Albania 4 257 1.48
Argentina 3 80 709 1.71 Andorra 457 5.91
Chile 27 799 2.20 Japan 6 42 756 0.34
Kuwait 3 491 0.74 Zambia 8 952 0.49
French Guiana 806 0.78 Niger 783 0.03
Suriname 550 1.42 Jamaica 581 0.20
Cape Verde 539 4.86 Maldives 335 0.62

Table 2

Countries that are in a state of recent decline"

Country / region Newly diagnosed
in the 54th week
Incidence density
in the 54th week/%
Country / region Newly diagnosed
in the 54th week
Incidence density
in the 54th week/%
Russia 1 165 520 1.13 Qatar 1 419 0.49
Germany 128 055 1.53 Saudi Arabia 1 031 0.03
South Africa 119 116 2.01 Kenya 905 0.02
Italy 114 533 1.89 Uganda 789 0.02
Poland 53 223 1.41 Mauritania 679 0.15
Ukraine 44 677 1.02 Syria 671 0.04
Sweden 34 063 3.37 The Republic of Congo 549 0.10
Romania 24 491 1.27 Angola 547 0.02
Switzerland 17 183 1.99 Uzbekistan 374 0.01
Belgium 13 071 1.13 Mali 373 0.02
Belarus 13 003 1.38 Reunion 196 0.22
Austria 12 331 1.37 Sierra Leone 177 0.02
Hungary 10 128 1.05 Guinea 161 0.01
Denmark 8 823 1.52 Bhutan 66 0.09
Slovenia 8 498 4.09 Sudan 0 0.00
Lithuania 8 498 3.12 Aruba 3 413 3.87
Costa Rica 6 835 1.34 United States Virgin Islands 88 0.84
Palestine 5 815 1.14 Pakistan 4 16 828 0.08
Croatia 5 228 1.27 Egypt 6 810 0.07
Puerto Rico 3 887 1.36 Bangladesh 5 795 0.04
Estonia 3 602 2.72 Kazakhstan 5 259 0.28
Moldova 3 594 0.89 Salvador 1 902 0.29
Montenegro 2 835 4.51 Oman 1 194 0.23
Armenia 2 441 0.82 Kyrgyzstan 848 0.13
Namibia 2 315 0.91 Afghanistan 538 0.01
Cyprus 1 935 1.60 Cameroon 488 0.02
Swaziland 1 354 1.17 Mongolia 96 0.03
Malta 1 235 2.80 South Sudan 89 0.01
Gibraltar 581 17.25 United Kingdom 5 358 547 5.28
Barbados 256 0.89 Czech Republic 61 190 5.71
San Marino 139 4.10 Netherlands 43 115 2.52
Monaco 128 3.26 Ireland 30 664 6.21
Jersey 121 1.22 Panama 22 194 5.14
Liechtenstein 62 1.63 Slovakia 17 516 3.21
India 2 129 424 0.09 Serbia 13 698 1.57
Nigeria 9 867 0.05 Norway 3 942 0.73
Morocco 7 404 0.20 Macedonia 2 795 1.34
Iraq 5 567 0.14 Bosnia and Herzegovina 2 411 0.73
Greece 4 366 0.42 Bahrain 1 991 1.17
Sri Lanka 4 289 0.20 Kosovo 1 871 0.94
Bulgaria 3 491 0.50 Luxembourg 882 1.41
Azerbaijan 3 132 0.31 Iran 6 43 781 0.52
Ethiopia 2 754 0.02 Korea 3 822 0.07
Nepal 2 657 0.09 Algeria 1 203 0.03
Finland 1 843 0.33 Burkina Faso 943 0.05
Thailand 1 839 0.03
[1] 中华预防医学会新型冠状病毒肺炎防控专家组. 新型冠状病毒肺炎流行病学特征的最新认识[J]. 中国病毒病杂志, 2020,10(2):86-92.
[2] Harapan H, Itoh N, Yufika A, et al. Coronavirus disease 2019 (COVID-19): a literature review[J]. J Infect Public Health, 2020,13(5):667-673.
doi: S1876-0341(20)30432-9 pmid: 32340833
[3] Ngonghala CN, Iboi EA, Gumel AB. Could masks curtail the post-lockdown resurgence of COVID-19 in the US[J/OL]. Math Biosci, 2020,329:108452(2020-08-18)[2021-01-01]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7431430/
[4] WHO. WHO coronavirus disease (COVID-19) dashboard[EB/OL]. (2020-01-16) [2021-01-17]. https://covid19.who.int.
[5] United Nations. World population prospects 2019[EB/OL]. (2019-8-28) [2020-11-29]. https://population.un.org/wpp/Download/Standard/Population/.
[6] Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia[J]. N Engl J Med, 2020,382(13):1199-1207.
doi: 10.1056/NEJMoa2001316
[7] Wang X, Tang SY, Chen Y, et al. When will be the resumption of work in Wuhan and its surrounding areas during COVID-19 epidemic? A data-driven network modeling analysis (in Chinese)[J]. Sci Sin Math, 2020,50(7):969-978.
doi: 10.1360/SSM-2020-0037
[8] 中华人民共和国国务院新闻办公室. 《抗击新冠肺炎疫情的中国行动》白皮书 [EB/OL]. (2020-06-07) [2020-11-28]. http://www.scio.gov.cn/ztk/dtzt/42313/43142/index.htm.
[9] Lai S, Ruktanonchai NW, Zhou L, et al. Effect of non-pharmaceutical interventions to contain COVID-19 in China[J]. Nature, 2020,585(7825):410-413.
doi: 10.1038/s41586-020-2293-x
[10] 国务院. 国务院应对新型冠状病毒感染肺炎疫情联防联控机制关于做好新冠肺炎疫情常态化防控工作的指导意见[J]. 中国公共卫生管理, 2020,36(3):284-441.
[11] United Nations. China shows COVID-19 coronavirus can be ‘stopped in its tracks’[EB/OL]. (2020-03-16) [2020-12-16]. https://news.un.org/en/story/2020/03/1059502.
[12] Yuan J, Li M, Lv G, et al. Monitoring transmissibility and mortality of COVID-19 in Europe[J]. Int J Infect Dis, 2020,95:311-315.
doi: 10.1016/j.ijid.2020.03.050
[13] Flaxman S, Mishra S, Gandy A, et al. Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe[J]. Nature, 2020,584(7820):257-261.
doi: 10.1038/s41586-020-2405-7 pmid: 32512579
[14] Glass DH. European and US lockdowns and second waves during the COVID-19 pandemic[J/OL]. Math Biosci, 2020,330:108472(2020-09-24)[2021-01-01]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7832121/.
[15] 中央纪委国家/地区监委网站. 分析:欧洲疫情为何反弹 [EB/OL]. (2020-10-30) [2020-11-24]. http://www.ccdi.gov.cn/yaowen/202010/t20201030_228981.html.
[16] 高雅. 专访美国公共卫生专家黄严忠为何新冠肺炎疫情如此反复[N]. 第一财经日报, 2020-07-02(A8).
[17] 常宇桐, 刘丽娟, 张丽萍, 等. 变异新冠病毒对口岸疫情防控影响的快速风险评估[J/OL]. 中国国境卫生检疫杂志 (2021-03-11)[2021-03-24]. http://kns.cnki.net/kcms/detail/11.3254.R.20210311.1726.002.html.
[18] Davies NG, Abbott S, Barnard RC, et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England[J/OL]. Science, 2021[2021-01-10]. https://science.sciencemag.org/content/372/6538/eabg3055.full.
[19] Volz E, Mishra S, Chand M, et al. Transmission of SARS-CoV-2 Lineage B.1.1.7 in England: insights from linking epidemiological and genetic data[J/OL]. MedRxiv, 2021 [2021-01-10]. https://www.medrxiv.org/node/223306.external-links.html.
[20] 张超, 陈姝冰, 张洁, 等. 浅析注册用于新冠肺炎治疗的临床试验药物[J]. 药学学报, 2020,55(3):355-365.
[21] Sjödin H, Wilder-Smith A, Osman S, et al. Only strict quarantine measures can curb the coronavirus disease (COVID-19) outbreak in Italy, 2020[J]. Euro Surveill, 2020,25(13):2000280.
[22] World Health Organization. Draft landscape and tracker of COVID-19 candidate vaccines[EB/OL]. (2021-02-23)[2021-03-02]. https:/www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines.
[23] 陈恩富. 疫苗时代新型冠状病毒肺炎疫情防控策略[J]. 预防医学, 2021,33(3):221-225.
[24] Scudellari M. How the pandemic might play out in 2021 and beyond[J]. Nature, 2020,584(7819):22-25.
doi: 10.1038/d41586-020-02278-5 pmid: 32760050
[1] Hong MENG,Li-na JI,Jing HUANG,Shuang CHAO,Jia-wen ZHOU,Xue-jun LI,Xiao-mei YIN,Li-rong FAN. Analysis of the changes and characteristics of pediatric outpatient visits in a general hospital in Beijing before and after the COVID-19 pandemic [J]. Journal of Peking University (Health Sciences), 2021, 53(5): 952-956.
[2] Qiu WANG,Jin-yu GUO,Hong SUN,Ling WANG,Ju-su YING,Hui-xin LIU. Investigation of protective exposure risk events in nurses against corona virus disease 2019 in Wuhan [J]. Journal of Peking University (Health Sciences), 2020, 52(4): 711-714.
[3] Hang YANG,Lin-cheng YANG,Rui-tao ZHANG,Yun-peng LING,Qing-gang GE. Risks factors for death among COVID-19 patients combined with hypertension, coronary heart disease or diabetes [J]. Journal of Peking University (Health Sciences), 2020, 52(3): 420-424.
[4] Mei-lian CHEN,Yan GAO,Wei GUO,Li ZUO,Tian-bing WANG. Infection prevention and control of bedside blood purification treatment in patients with COVID-19 [J]. Journal of Peking University (Health Sciences), 2020, 52(3): 414-419.
[5] Wen FENG,Liang-nan ZHANG,Jing-yuan LI,Tian WEI,Ting-ting PENG,Dong-xu ZHANG,Zai-xin GUO,Wei-song WANG. Analysis of special ehealth service for corona virus disease 2019 (COVID-19) pneumonia [J]. Journal of Peking University (Health Sciences), 2020, 52(2): 302-307.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
[1] Author. English Title Test[J]. Journal of Peking University(Health Sciences), 2010, 42(1): 1 -10 .
[2] . [J]. Journal of Peking University(Health Sciences), 2009, 41(2): 188 -191 .
[3] . [J]. Journal of Peking University(Health Sciences), 2009, 41(3): 376 -379 .
[4] . [J]. Journal of Peking University(Health Sciences), 2009, 41(4): 459 -462 .
[5] . [J]. Journal of Peking University(Health Sciences), 2010, 42(1): 82 -84 .
[6] . [J]. Journal of Peking University(Health Sciences), 2007, 39(3): 319 -322 .
[7] . [J]. Journal of Peking University(Health Sciences), 2007, 39(3): 333 -336 .
[8] . [J]. Journal of Peking University(Health Sciences), 2007, 39(3): 337 -340 .
[9] . [J]. Journal of Peking University(Health Sciences), 2007, 39(3): 225 -328 .
[10] . [J]. Journal of Peking University(Health Sciences), 2007, 39(4): 346 -350 .